EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network

Eleanor Kane iD, Alexandra Smith iD, Debra Howell iD, Catherine Cargo iD, Kate Rothwell, Simone Green, Russell Patmore iD, Eve Roman iD

International Journal of Cancer · 15.09.2026 · 159 (6) · 1411-1419

DOI: 10.1002/ijc.70518 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 29.04.2026. Verfasst von Eleanor Kane und 7 weiteren Autor:innen. Beteiligte Einrichtung: Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Cardiovascular Diseases. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK and Blood Cancer UK, National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC), Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Outcomes among patients with chronic myeloid leukaemia (CML) improved markedly when tyrosine kinase inhibitors (TKIs) were introduced into routine clinical practice around the turn of the century. Nonetheless, adverse events still occur, survival remains suboptimal and the long‐term health impact of the disease and its treatment is poorly understood. Using data from an established UK population‐based cohort of haematological malignancies, we compared the morbidity of 411 CML patients treated with TKIs 2009–2019 to that of individually age‐ and sex‐matched general population‐based controls ( n = 4099). Over the course of follow‐up (to March 2021, median 5.3, interquartile range 3.0–8.2 years), patients were more likely than controls to die from cardiovascular or respiratory diseases; Hazard Ratios of 1.9, 95% Confidence Interval, 95% CI = 1.2–2.8 and 2.4, 95% CI 1.2–4.9 respectively. Hospital admissions for cardiovascular or respiratory conditions were similarly elevated; HR = 1.6, 95% CI 1.3–1.9; HR = 2.3, 95% CI 1.6–3.4 respectively. The risk of a cardiovascular admission varied over time; being increased in the first year (HR = 2.4, 95% CI 1.5–3.8), and then again 5 years or more after starting TKI therapy (HR = 2.3, 95% CI 1.5–3.6); no increase was evident in the intervening years (HR = 1.1, 95% CI 0.8–1.7). While not related to excess mortality, admissions for infections and gastrointestinal conditions occurred more frequently among cases than controls; the increased risk remaining largely constant over the course of follow‐up. In the era of TKIs, these real‐world analyses revealed that CML patients are at increased risk of severe cardiovascular events several years after starting treatment, and that admission for infections and gastrointestinal conditions are raised throughout.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsCardiovascular DiseasesHumansFemaleMaleUnited KingdomMiddle AgedAgedAdultRespiratory Tract DiseasesCase-Control Studies

Stichwörter der Autor:innen

cardiovascular eventschronic myeloid leukaemiamorbiditymortalitytyrosine kinase inhibitor

Substanzen

Protein Kinase Inhibitors

Autor:innen und Institutionen

  • Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
  • Haematological Malignancy Diagnostic Service, St James's University Hospital, Leeds, UK.
  • Department of Clinical Haematology, Leeds Teaching Hospital NHS Trust, Leeds, UK.
  • Queen's Centre for Oncology and Haematology, Castle Hill Hospital, Cottingham, UK.

ORCID-Profile: Eleanor Kane, Alexandra Smith, Debra Howell, Catherine Cargo, Russell Patmore, Eve Roman

Förderung

  • Cancer Research UK and Blood Cancer UK
  • National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC)
  • Cancer Research UK
  • National Institute for Health and Care Research

Zitieren

APA

Kane, E., Smith, A., Howell, D., Cargo, C., Rothwell, K., Green, S., Patmore, R., & Roman, E. (2026). Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network. International Journal of Cancer, 159(6), 1411-1419. https://doi.org/10.1002/ijc.70518

Vancouver

Kane E, Smith A, Howell D, Cargo C, Rothwell K, Green S, et al. Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network. International Journal of Cancer. 2026;159(6):1411-1419. doi:10.1002/ijc.70518

BibTeX
@article{Kane2026,
  author = {Kane, Eleanor and Smith, Alexandra and Howell, Debra and Cargo, Catherine and Rothwell, Kate and Green, Simone and Patmore, Russell and Roman, Eve},
  title = {Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK 's Haematological Malignancy Research Network},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {6},
  pages = {1411--1419},
  doi = {10.1002/ijc.70518}
}
Kostenlos starten →